/wp-content/uploads/4dmt_logo.svg00Erik Allison/wp-content/uploads/4dmt_logo.svgErik Allison2024-05-07 11:13:542024-05-08 14:34:08Interim Results from the PRISM Randomized Phase 2 Dose Expansion Trial Evaluating 4D-150 in High Anti-VEGF Need Individuals with Neovascular (Wet) Age-Related Macular Degeneration
/wp-content/uploads/4dmt_logo.svg00Erik Allison/wp-content/uploads/4dmt_logo.svgErik Allison2024-02-09 09:44:412024-02-09 09:44:41Phase 1/2 Clinical Trial Evaluating 4D-310 in Adults with Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 12–33 Months of Follow-up
/wp-content/uploads/4dmt_logo.svg00David Anderson/wp-content/uploads/4dmt_logo.svgDavid Anderson2024-02-02 17:38:562024-02-09 09:45:36First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD
/wp-content/uploads/4dmt_logo.svg00David Anderson/wp-content/uploads/4dmt_logo.svgDavid Anderson2023-10-03 08:00:102023-11-28 10:10:21Targeting the Complement Pathway with AAV-Based Gene Therapy for Geographic Atrophy
/wp-content/uploads/4dmt_logo.svg00David Anderson/wp-content/uploads/4dmt_logo.svgDavid Anderson2023-07-28 14:54:142023-07-28 14:54:14Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration